Search results for Intellia Therapeutics

Intellia races in vivo CRISPR therapy to FDA after phase 3 data paint ‘compelling’ picture

A phase 3 trial of Intellia Therapeutics’ in vivo gene editing therapy lonvoguran ziclumeran has hit its primary endpoint, leading the biotech to start a rolling submission for FDA...

Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder

The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial potential remains the source of intense investor debate...

Intellia Drops Counterclaims In Gene-Editing Patent Case

Intellia Therapeutics Inc. has agreed to drop a set of claims it asserted in a Delaware federal suit brought by BlueAllele, which accused it of infringing three gene-editing patent...

Intellia’s Data Reveal Tees Up FDA Filing for CRISPR-Based In Vivo Gene-Editing Med

Intellia Therapeutics’ lonvo-z uses CRISPR to inactivate a gene in the liver to reduce levels of a protein key to the swelling attacks from the rare disease hereditary angioedema....

Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update

Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antit...

What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer.

The biotech's candidate may treat a great number of illnesses that have one thing in common.

Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM

Shares of Immunovant, Alto and Oric Pharmaceuticals fell this week on clinical trial updates. Elsewhere, Orca Bio’s cell therapy hit a delay and Korsana entered a reverse merger.

‘Type’ Casting: Flagship-Founded Serif Modifying DNA into New Therapy Class

Flagship Pioneering has formally launched Serif with an initial commitment of $50 million in financing—capital that Serif intends to use toward developing its scalable platform for...

<![CDATA[Neurocrine Enters $2.9 Billion Agreement to Acquire Soleno Therapeutics ]]>

With $50M from Flagship Pioneering, Serif strives to write new chapter for DNA medicines

With a few chemical tweaks and some dutiful protein partners, a new biotech from Flagship Pioneering thinks it has cracked the code to turn DNA into a brand-new class of therapeuti...

<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Ther...

Coultreon banks $125M to support testing of former Galapagos immune drug

Backed by Novo Holdings, Regeneron’s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating many immunological dise...

Neurocrine Is Making a $2.9 Billion Bet on a New Kind of Drug

The company is acquiring Soleno Therapeutics to add a newly approved Prader‑Willi syndrome treatment to its portfolio.

Lilly pens $2.2B pact with Bezos-backed Profluent to work on recombinase-based gene editing

Eli Lilly’s latest attempt to strengthen its genetic medicine offering has seen the pharma team up with Profluent to develop AI-designed recombinases to address diseases with sever...

<![CDATA[Obsidian Therapeutics and Galera Therapeutics Enter $350 Million Merger Agreement]]>

Lilly pens $202M deal for preclinical DNA delivery biotech Engage as M&A streak continues

San Carlos-based Engage is developing non-viral DNA delivery systems that aim to overcome traditional limitations associated with the modality.

Eli Lilly Makes Another In Vivo Genetic Medicines Move With $3.2B Kelonia Acquisition

Kelonia Therapeutics brings to Eli Lilly an in vivo cell therapy in early clinical development for multiple myeloma. The deal complements Lilly’s acquisitions of Verve Therapeutic...

Lilly boosts ‘in vivo’ cell therapy capabilities with Kelonia buyout

Worth up to $7 billion, Lilly’s second recent acquisition of a company in the space is centered around a cell therapy that’s currently in early-stage testing for multiple myeloma.

Odyssey’s IPO Brings In $304M for Quest to Develop Better Immunology Drugs

Ulcerative colitis is the lead indication for Odyssey Therapeutics’ internally discovered lead drug candidate. With the IPO proceeds, Odyssey plans mid-stage clinical trials evalua...

Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial

Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boos...

<![CDATA[Regeneron Enters $2.1 Billion Radiopharma Collaboration with Telix Pharmaceuticals ]]>

Tango Therapeutics: 'Hold' On Combination Strategy Shift Of Vopimetostat

Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine

The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger RNA to gene therapy. 

Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval

This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.